Health

A groundbreaking study has shed light on the potential benefits of a triplet combination involving brentuximab vedotin (BV) for patients with diffuse large B-cell lymphoma (DLBCL). The study demonstrated that this combination therapy, consisting of BV, lenalidomide, and rituximab, led to significant improvements in overall survival (OS) compared to lenalidomide-rituximab alone in the third-line setting.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a challenging disease to diagnose and treat due to its rarity and heterogeneity. Current standard treatments like intravenous immunoglobulin (IVIG), steroids, and plasma exchange are not always effective, especially in certain CIDP phenotypes. This has prompted the search for valid biomarkers that can aid in both the diagnosis and